Related references
Note: Only part of the references are listed.AP-1 and NF-κB synergize to transcriptionally activate latent HIV upon T-cell receptor activation
Joseph Hokello et al.
FEBS LETTERS (2021)
Integrated Assessment of Viral Transcription, Antigen Presentation, and CD8+ T Cell Function Reveals Multiple Limitations of Class I-Selective Histone Deacetylase Inhibitors during HIV-1 Latency Reversal
Talia M. Mota et al.
JOURNAL OF VIROLOGY (2020)
Proteasomal Inhibition Potentiates Latent HIV Reactivation
Daniele C. Cary et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2020)
Identification of Combinations of Protein Kinase C Activators and Histone Deacetylase Inhibitors that Potently Reactivate Latent HIV
Francesca Curreli et al.
VIRUSES-BASEL (2020)
HIV shock and kill therapy: In need of revision
Erik Abner et al.
ANTIVIRAL RESEARCH (2019)
Dual effects of the novel ingenol derivatives on the acute and latent HIV-1 infections
He Yang et al.
ANTIVIRAL RESEARCH (2019)
Potential of the NKG2D/NKG2DL Axis in NK Cell-Mediated Clearance of the HIV-1 Reservoir
Maria G. Desimio et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations
Judith Grau-Exposito et al.
PLOS PATHOGENS (2019)
In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV plus individuals
Carolina Garrido et al.
AIDS (2019)
Latency-Reversing Agents Induce Differential Responses in Distinct Memory CD4 T Cell Subsets in Individuals on Antiretroviral Therapy
Marion Pardons et al.
CELL REPORTS (2019)
Between a shock and a hard place: challenges and developments in HIV latency reversal
Jennifer M. Zerbato et al.
CURRENT OPINION IN VIROLOGY (2019)
T cell toxicity of HIV latency reversing agents
Manzhi Zhao et al.
PHARMACOLOGICAL RESEARCH (2019)
Reiterative Enrichment and Authentication of CRISPRi Targets (REACT) identifies the proteasome as a key contributor to HIV-1 latency
Zichong Li et al.
PLOS PATHOGENS (2019)
Hexamethylene bisacetamide impairs NK cell-mediated clearance of acuteT lymphoblastic leukemia cells and HIV-1-infected T cells that exit viral latency
Erica Giuliani et al.
SCIENTIFIC REPORTS (2019)
Novel Latency Reversal Agents for HIV-1 Cure
Adam M. Spivak et al.
ANNUAL REVIEW OF MEDICINE, VOL 69 (2018)
Getting the Kill into Shock and Kill: Strategies to Eliminate Latent HIV
Youry Kim et al.
CELL HOST & MICROBE (2018)
Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo
Carolina Garrido et al.
JOURNAL OF VIROLOGY (2018)
Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression
Thomas D. Zaikos et al.
JOURNAL OF VIROLOGY (2018)
TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy
So-Yon Lim et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents
Matthew D. Marsden et al.
VIROLOGY (2018)
Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
Amit Kumar Singh et al.
NUTRIENTS (2018)
In Vitro Exposure to Prostratin but Not Bryostatin-1 Improves Natural Killer Cell Functions Including Killing of CD4+ T Cells Harboring Reactivated Human Immunodeficiency Virus
Maria Giovanna Desimio et al.
FRONTIERS IN IMMUNOLOGY (2018)
Dual TLR2 and TLR7 agonists as HIV latency-reversing agents
Amanda B. Macedo et al.
JCI INSIGHT (2018)
TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells
Rujuta A. Bam et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency
Nancie M. Archin et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy
Angela Tsai et al.
JOURNAL OF VIROLOGY (2017)
Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective
Loredana Cifaldi et al.
TRENDS IN MOLECULAR MEDICINE (2017)
The histone deacetylase inhibitor SAHA simultaneously reactivates HIV-1 from latency and up-regulates NKG2D ligands sensitizing for natural killer cell cytotoxicity
Maria Giovanna Desimio et al.
VIROLOGY (2017)
In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell kick and kill in strategy for virus eradication
Matthew D. Marsden et al.
PLOS PATHOGENS (2017)
Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance
Alessandra Zingoni et al.
FRONTIERS IN IMMUNOLOGY (2017)
The histone deacetylase inhibitor valproic acid inhibits NKG2D expression in natural killer cells through suppression of STAT3 and HDAC3
Lulu Ni et al.
SCIENTIFIC REPORTS (2017)
Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation
Brice J. Albert et al.
SCIENTIFIC REPORTS (2017)
Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection
Line Vibholm et al.
CLINICAL INFECTIOUS DISEASES (2017)
In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors
Riddhima Banga et al.
JOURNAL OF VIROLOGY (2016)
Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy
Carolina Gutierrez et al.
AIDS (2016)
Heat Shock Protein 90 Facilitates Latent HIV Reactivation through Maintaining the Function of Positive Transcriptional Elongation Factor b (p-TEFb) under Proteasome Inhibition
Xiao-Yan Pan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function
G. Clutton et al.
Scientific Reports (2016)
Histone Deacetylase Inhibitors Enhance CD4 T Cell Susceptibility to NK Cell Killing but Reduce NK Cell Function
Matthew Pace et al.
PLOS PATHOGENS (2016)
HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function
Carolina Garrido et al.
FRONTIERS IN IMMUNOLOGY (2016)
The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication
Victoria E. Walker-Sperling et al.
EBIOMEDICINE (2016)
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations
Gregory M. Laird et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat
Rikke Olesen et al.
JOURNAL OF VIROLOGY (2015)
Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1
Marta Martinez-Bonet et al.
SCIENTIFIC REPORTS (2015)
An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression
Gilles Darcis et al.
PLOS PATHOGENS (2015)
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
Ole S. Sogaard et al.
PLOS PATHOGENS (2015)
Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study
Julian H. Elliott et al.
LANCET HIV (2015)
TLR7 induces anergy in human CD4+ T cells
Margarita Dominguez-Villar et al.
NATURE IMMUNOLOGY (2015)
The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells
Shiguo Zhu et al.
PHARMACEUTICAL RESEARCH (2015)
A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral Therapy
Adam M. Spivak et al.
CLINICAL INFECTIOUS DISEASES (2014)
New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo
C. Korin Bullen et al.
NATURE MEDICINE (2014)
Heat shock protein 90 controls HIV-1 reactivation from latency
Ian Anderson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy
Julian H. Elliott et al.
PLOS PATHOGENS (2014)
Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes
Richard Brad Jones et al.
PLOS PATHOGENS (2014)
Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing
Datsen George Wei et al.
PLOS PATHOGENS (2014)
Cancer-inducecd alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity
Anne-Sophie Chretien et al.
FRONTIERS IN IMMUNOLOGY (2014)
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
Thomas A. Rasmussen et al.
LANCET HIV (2014)
Regulation of Ligands for the NKG2D Activating Receptor
David H. Raulet et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells
Giulia Matusali et al.
FASEB JOURNAL (2013)
Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo
Elizabeth J. Beans et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Midkine upregulates MICA/B expression in human gastric cancer cells and decreases natural killer cell cytotoxicity
Shuli Zhao et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma
Philippe Moreau et al.
CLINICAL PHARMACOKINETICS (2012)
Stimulation of HIV-1-Specific Cytolytic T Lymphocytes Facilitates Elimination of Latent Viral Reservoir after Virus Reactivation
Liang Shan et al.
IMMUNITY (2012)
Effect of Histone Deacetylase Inhibitors on HIV Production in Latently Infected, Resting CD4+ T Cells From Infected Individuals Receiving Effective Antiretroviral Therapy
Jana Blazkova et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
N. M. Archin et al.
NATURE (2012)
Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection
Seiko Iwata et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing
Jonathan Richard et al.
BLOOD (2010)
Bryostatin-1 Synergizes with Histone Deacetylase Inhibitors to Reactivate HIV-1 from Latency
Moises Perez et al.
CURRENT HIV RESEARCH (2010)
Combinatorial Latency Reactivation for HIV-1 Subtypes and Variants
John C. Burnett et al.
JOURNAL OF VIROLOGY (2010)
A Limited Group of Class I Histone Deacetylases Acts To Repress Human Immunodeficiency Virus Type 1 Expression
Kara S. Keedy et al.
JOURNAL OF VIROLOGY (2009)
Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs
Mayte Coiras et al.
NATURE REVIEWS MICROBIOLOGY (2009)
Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection
Sophie Reuse et al.
PLOS ONE (2009)
HIV-1 Vpr Triggers Natural Killer Cell-Mediated Lysis of Infected Cells through Activation of the ATR-Mediated DNA Damage Response
Jeffrey Ward et al.
PLOS PATHOGENS (2009)
Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors
Mar Vales-Gomez et al.
CANCER RESEARCH (2008)
Lysis of endogenously infected CD4+T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals
Manuela Fogli et al.
PLOS PATHOGENS (2008)
Histone deacetylase inhibitors suppress natural killer cell cytolytic activity
Henry Ogbomo et al.
FEBS LETTERS (2007)
Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity
Cristina Cerboni et al.
JOURNAL OF GENERAL VIROLOGY (2007)
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors
P Bali et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Share Paper
